BREAST CANCER

项目摘要(见说明)；流行病学和癌症控制计划由来自12个部门的34名调查人员(30名正式成员和4名准成员)组成。该计划的总体使命是降低癌症发生和死亡的风险，并提高癌症幸存者的生活质量。为了完成这一使命，它有四个主要的科学目标：1)确定癌症的环境和遗传决定因素，以改进癌症预防手段，特别是侧重于了解环境因素在癌症病因学中的作用，确定癌症病因学中的代谢和生殖因素，了解人类遗传学在癌症病因和进展中的作用，以及确定与人类微生物群有关的癌症风险；2)通过风险因素修改来减少癌症负担，特别是肥胖控制和减少烟草使用；3)通过及早发现癌症来减轻癌症负担，特别注重应用各种方法，增加未得到充分服务的人群的筛查参与率，并开发新的早期检测生物标记物；以及4)解决患者和幸存者与癌症有关的负担，特别强调满足未得到充分服务的人的需求。研究的重点领域是跨学科的，包括来自ECC和其他纽约大学癌症研究所研究项目的人口、实验室和临床科学家。理查德·海斯博士和布莱恩·施密特博士是该项目的联合负责人。这是一个新项目，目前有16,940,943美元的资金。这一期间的出版物共计216份，其中17.6%是方案内出版物，11.1%是方案间出版物，8.8%是方案内和方案间合作出版物。相关性(见说明)：流行病学和癌症控制计划对癌症进行流行病学研究，并评估癌症预防和推广工作，从而为纽约地区乃至更广泛的不同地区人口有效的癌症减负计划提供证据基础。项目概要(见说明)：乳腺癌项目由来自17个部门的38名研究人员(32名正式成员和6名准成员)组成。该计划旨在将文化差异和基于人群的研究与以实验室为基础的基础、转化和临床研究计划相结合，通过对乳腺癌和治疗创新方法的协同理解来改变乳腺癌死亡率的状况。为此，他们制定了以下具体目标：1)了解阻碍诊断和护理并导致治疗和生存差异的文化和经济因素；2)了解导致乳腺癌发生、侵袭、复发和转移的免疫学、微环境、遗传和分子机制；3)将乳腺癌发生和发展的科学发现转化为创新的治疗方法和治疗方法，通过改进诊断和治疗使患者受益；4)促进临床医生和研究科学家的发展，共同建立新的基础、翻译和临床研究领域。为了实现这些目标，正在开发六个主要领域：1)激素信号；2)侵袭、转移和血管生成；3)免疫/免疫干预及其与乳腺癌的关系；4)流行病学；5)乳腺癌的放射生物学和物理学研究；6)社会文化和社区研究和计划。西尔维娅·福尔门蒂博士和罗伯特·施奈德博士是该项目的联合负责人。自上次竞争性申请以来，资金总额从9 789 777美元增加到11 595 777美元。会员人数从44人减少到38人。这一期间的出版物总数为275份，其中16.7%是方案内出版物，16%是方案间出版物，8.7%是方案内和方案间合作出版物。

PROJECT SUMMARY (See instructions); The Epidemiology & Cancer Control Program is composed of 34 investigators (30 Full and 4 Associate members) from 12 Departments. The overall mission of the Program is to reduce the risk of cancer occurrence and death and to enhance the quality of life of cancer survivors. To fulfill this mission, it has 4 major scientific objectives: 1) To identify environmental and genetic determinants of cancer to improve means of cancer prevention, focusing specifically on understanding the role of environmental factors in cancer etiology, determining the metabolic and reproductive factors in cancer etiology, understanding the role of human genetics in cancer etiology and progression, and identifying cancer risks associated with the human microbiome; 2) To reduce cancer burden by risk factor modification, with a specific focus on obesity control and tobacco use reduction; 3) To reduce cancer burden by early detection of cancer, with a specific focus on the application of methods to increase screening participation by underserved populations and the development of novel early detection biomarkers; and 4) To address cancer-related burden in patients and survivors, with a particular emphasis on meeting the needs of the underserved. The research focus areas are interdisciplinary, including population, laboratory and clinical scientists from ECC and other NYU Cancer Institute Research Programs. Drs. Richard Hayes and Brian Schmidt are the Co-Leaders for this Program. This is a new Program that currently has $16,940,943 on funding. Publications for the period total 216, of which 17.6% are intra-programmatic, 11.1% are inter-programmatic, and 8.8% are both intra- and interprogrammatic collaborations. RELEVANCE (See instructions): The Epidemiology and Cancer Control Program undertakes epidemiological research on cancer and evaluates cancer prevention and outreach efforts, thus contributing to the evidence-base for effective cancer burden reduction programs in the diverse New York regional population and more broadly. PROJECT SUMMARY (See instructions): The Breast Cancer Program is composed of 38 investigators (32 Full and 6 Associate members) from 17 Departments. The Program aims to integrate so do-cultural disparities and population-based research with laboratory-based basic, translational and clinical research programs that can change the state of breast cancer mortality through a synergistic understanding of breast cancer and innovative approaches in treatment. To do so, they have developed the following Specific Aims: 1) Understand the so do-cultural and economic factors that impede diagnosis and care and contribute to disparities in treatment and survival; 2) Understand the immunological, micro-environmental, genetic and molecular mechanisms that contribute to the development, invasion, recurrence and metastasis of breast cancer; 3) Translate scientific findings to breast cancer development and progression into innovative therapeutics and therapeutic approaches to benefit patients by improving diagnosis and treatment; and 4) Advance the development of clinicians and research scientists working collaboratively to establish novel basic, translational and clinical research areas. To address these aims, six major areas are being developed: 1) Hormonal signaling; 2) Invasiveness, metastasis and angiogenesis; 3) Immunity/immunological intervention and association with breast cancer; 4) Epidemiology; 5) Radiobiology and physics research in breast cancer; and 6) Socio-cultural and community based research and programs. Drs. Silvia Formenti and Robert Schneider are the Co-Leaders for this Program. Total funding increased from $9,789,777 to $11,595,777 since the last competitive application. Membership has decreased from 44 to 38. Publications for the period total 275, of which 16.7% are intraprogrammatic, 16% are inter-programmatic, and 8.7% are both intra- and inter-programmatic collaborations.